Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights

On November 9, 2026 Tango Therapeutics, Inc. (NASDAQ: TNGX) a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer, reported financial results for the third quarter ended September 30, 2026, and provided business highlights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In 2026, Tango has made significant strides towards bringing vopimetostat to patients with pancreatic cancer," said Malte Peters, MD, President and Chief Executive Officer of Tango. "This progress is rooted first in the data. Last month at ESMO (Free ESMO Whitepaper), we shared promising data from the combination of vopimetostat plus daraxonrasib that reinforced the potential of this program to raise the bar for patients with MTAP-deleted and RAS-mutant pancreatic cancer. Based on those data, we have engaged with the FDA on our plans for a registrational study in the front-line setting and plan to initiate that study in the first half of next year. In addition, we plan to engage with regulators on the possibility of seeking accelerated approval of this combination in second line pancreatic cancer. Beyond pancreatic cancer, we look forward to sharing our strategy in lung cancer, supported by data from vopimetostat and TNG456, in January of next year. I am grateful to the dedicated Tango team for the progress we have made in 2026 thus far and look forward to advancing our mission of bringing these important therapies to patients with cancer."

Clinical Pipeline Updates

ESMO DATA. In October 2026, Tango reported promising updated data from vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors daraxonrasib or zoldonrasib in patients with MTAP-deleted, RAS-mutant pancreatic cancer. Data demonstrated that vopimetostat in combination with daraxonrasib achieved an 82% objective response rate (ORR) and 88% nine-month progression-free survival (PFS) rate in efficacy-evaluable patients with second and third line pancreatic ductal adenocarcinoma (PDAC), and median PFS was not yet reached. Efficacy-evaluable patients are those patients who received their first dose of treatment at least 14 weeks prior to the data cutoff date of August 20, 2026. As of the data cutoff date, the combination had a generally well-tolerated safety profile at dose level one (vopimetostat 200 mg/daraxonrasib 100 mg QD).

PIVOTAL STUDY PLANS. Based upon the encouraging Phase 1/2 data and discussions with the US Food and Drug Administration (FDA), Tango intends to initiate a pivotal Phase 3 study of the combination of vopimetostat plus daraxonrasib in front-line MTAP-deleted pancreatic cancer. The Company anticipates that this will be a global, randomized study of vopimetostat 200 mg plus daraxonrasib 100 mg, once-daily vs. standard-of-care chemotherapy. The planned study has dual primary endpoints of ORR and PFS, with overall survival as a key secondary endpoint. The Company plans to initiate the study in the first half of 2027. In addition, Tango intends to discuss the possibility of pursuing approval of this combination in patients with second line PDAC with regulatory authorities.

ERASCA STUDY START. In November 2026, the Company announced that the Phase 1/2 study of oral PRMT5 inhibitor vopimetostat in combination with pan-RAS molecular glue ERAS-0015 in patients with MTAP-deleted PDAC and MTAP-deleted/RAS-mutant non-small cell lung cancer (NSCLC) has initiated enrollment.

LEADERS IN PRMT5 INHIBITION. In October 2026, the Company announced that it plans to initiate a Phase 1/2 combination study of vopimetostat plus panRAS inhibitors in patients with MTAP-wild type pancreatic cancer in the first half of 2027. This study of approximately 25 patients will explore the Company’s hypothesis, based on a strong biological rationale and emerging clinical and preclinical data, that the synergy observed in MTAP-deleted cancers has the potential to extend to MTAP-wild type cancers.

Corporate Updates

FOCUS ON PRMT5. In October 2026, Tango disclosed a strategic reprioritization of the Company’s research and development activities to focus on the advancement of PRMT5-targeted therapies.

Upcoming Expected Milestones

Disclose vopimetostat lung cancer monotherapy data in January 2027
Disclose TNG456 data in lung cancer, glioblastoma and other cancers in January 2027
Initiate a Phase 3 randomized-controlled trial of vopimetostat plus daraxonrasib in front-line MTAP-deleted pancreatic cancer in 1H 2027
Initiate Phase 1/2 vopimetostat plus panRAS inhibitor study in MTAP-wild type pancreatic cancer in 1H 2027

Financial Results

As of September 30, 2026, the Company held $977.5 million in cash, cash equivalents and marketable securities, which the Company expects to fund its current operating plan.

Collaboration revenue was $0 for the three months ended September 30, 2026, compared to $53.8 million for the same period in 2025, and $0 for the nine months ended September 30, 2026, compared to $62.4 million for the same period in 2025. All remaining deferred revenue from the upfront and research option-extension payments under the Gilead collaboration was recognized as collaboration revenue during the year ended December 31, 2025 as a result of the truncation of the collaboration agreement which concluded all research activities in August 2025.

Research and development expenses were $48.9 million for the three months ended September 30, 2026, compared to $30.8 million for the same period in 2025, and $119.7 million for the nine months ended September 30, 2026, compared to $100.1 million for the same period in 2025. The change was primarily due to increased spend related to the advancement of the vopimetostat and TNG456 clinical programs. This increase was partially offset by decreased spend due to the Company’s portfolio prioritization efforts.

General and administrative expenses were $29.2 million for the three months ended September 30, 2026, compared to $8.9 million for the same period in 2025, and $67.0 million for the nine months ended September 30, 2026, compared to $31.7 million for the same period in 2025. The increase was primarily due to increased spend on personnel-related costs, including share-based compensation expense which included increases derived from the modification of previously issued equity awards for former executive officers.

Net loss for the three months ended September 30, 2026 was $68.4 million, or $0.39 per share (basic and diluted), compared to a net income of $15.9 million, or $0.14 per share (basic) and $0.13 per share (diluted), in the same period in 2025. Net loss for the nine months ended September 30, 2026 was $169.2 million, or $1.08 per share (basic and diluted), compared to a net loss of $62.8 million, or $0.57 per share (basic and diluted), in the same period in 2025.

(Press release, Tango Therapeutics, NOV 9, 2026, View Source [SID1234674526])

Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update

On November 9, 2026 Foghorn Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines against challenging targets in oncology and immunology & inflammation (I&I), reported a financial and corporate update in conjunction with the Company’s 10-Q filing for the third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our focus is on advancing our wholly owned portfolio, including our novel, oral I&I program in IBD, with potential for first-in-human trials by the end of 2027, and our Selective EP300 degrader which has an IND targeted for next year," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn Therapeutics. "We are also advancing a novel induced-proximity approach with the potential to deliver antibody-like efficacy against high-value secreted and transmembrane proteins through small molecules. With cash runway into the second half of 2029, we are well positioned to deliver on this strategy."
Program Overview and Upcoming Milestones
Novel oral I&I program. Foghorn is advancing a novel oral small-molecule inhibitor with an initial focus in IBD. Preclinical data demonstrate robust suppression of disease activity in a T-cell transfer colitis model and an IL-10 knock-out model, with efficacy comparable to an anti-IL-12/23p40 antibody positive control.
•Dose-range finding studies are expected to begin in the fourth quarter of 2026, with potential first-in-human studies by the end of 2027.

Selective EP300 degrader program. Foghorn is developing a Selective EP300 degrader for the treatment of hematological malignancies. Attempts to selectively drug EP300 have been challenging due to the high level of similarity between EP300 and CBP, and dual inhibition of CBP/EP300 has been associated with dose limiting toxicities. EP300 lineage dependencies are established in diffuse large b-cell lymphoma (DLBCL), MM, and other heme malignancies.
•EP300 degrader program outperforms clinical benchmark. Preclinical data highlight the therapeutic potential in MM including superior anti-tumor activity with complete responses, compared to clinical benchmark dual CBP/EP300 inhibitor inobrodib. Superior safety by body weight loss and platelet counts over dual inhibition, and tumor regression in a multiple myeloma xenograft model of acquired pomalidomide resistance were also observed.
•IND targeted in 2027, with a focus in MM and DLBCL.

Endoplasmic Reticulum Induced Proximity (ERIP). Foghorn is advancing a novel small-molecule induced-proximity approach to degrade secreted and transmembrane proteins before they reach the cell surface or circulation. The approach has the potential to address high-value targets in I&I, oncology, and other disease areas with the goal of achieving antibody-like efficacy through small molecules.
Third Quarter 2026 Financial Highlights
•Collaboration Revenue. Collaboration revenue was $83.5 million for the three months ended September 30, 2026, compared to $8.2 million for the three months ended September 30, 2025. The $75.4 million increase was driven by a $74.1 million cumulative catch-up adjustment primarily related to updated estimated future costs for the decision to not advance FHD-909 and the SMARCA2 selective degrader.

•Research and Development Expenses. Research and development expenses were $18.8 million for the three months ended September 30, 2026, compared to $20.0 million for the three months ended September 30, 2025. The $1.2 million decrease is attributed to a decrease in Lilly-partnered program costs, decreases in facilities and IT-related expenses, and decreases in personnel-related costs, partially offset by an increase in early development and other external costs.

•General and Administrative Expenses. General and administrative expenses were $5.8 million for the three months ended September 30, 2026, compared to $6.7 million for the three months ended September 30, 2025. This $0.9 million decrease was due to a decrease in personnel related costs, decreases professional and consulting costs, and lower facilities and IT-related expenses.

•Net Income (Loss). Net income was $58.2 million for the three months ended September 30, 2026, compared to a net loss of $15.8 million for the three months ended September 30, 2025.

•Cash, Cash Equivalents, and Marketable Securities. As of September 30, 2026, the Company had $156.2 million in cash, cash equivalents, and marketable securities, providing cash runway into the second half of 2029.

(Press release, Foghorn Therapeutics, NOV 9, 2026, View Source [SID1234674471])

Transgene Reports Continued Clinical Progress and Q3 2026 Financial Update

On November 9, 2026 Transgene (Euronext Paris: TNG), a biotech company developing myvac, an individualized neoantigen therapeutic vaccines (INTV) platform designed to prevent cancer recurrence, alongside a portfolio of viral vector-based candidates, reported a business update on its myvac-based individualized assets TG4050 and TG4070, its upcoming plans, and its financial position as of September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TG4050: 100% DFS sustained after more than 3 years of follow-up

Strong Phase 1 data from the randomized Phase 1/2 trial (NCT04183166), demonstrating the potential of TG4050 to prevent recurrence in patients early-stage HNSCC at high risk of relapse following surgery and (chemo)-radiotherapy, have been published in Nature Communications (see press release). TG4050 showed a favorable safety profile and induced persistent neoantigenspecific T cell responses, with a 100% disease-free survival (DFS) rate sustained after more than three years of follow-up.

The Phase 2 part of the study is ongoing. First immunological data are expected by year end, with the aim of presenting them at a scientific conference in 2027. Transgene expects to communicate topline results from TG4050’s Phase 2 trial by the end of Q1 2028.

In parallel, Transgene continues to strengthen its manufacturing capabilities in preparation for a potential Phase 3 trial in HNSCC. This includes transitioning TG4050 into a scalable cell linebased manufacturing process.

The Company remains on track to have Phase 3-ready manufacturing capacity by the end of 2027.

TG4070: all French clinical sites open, enabling patient recruitment to begin

TG4070, Transgene’s second Individualized Neoantigen Therapeutic Vaccine (INTV) candidate, represents an important strategic expansion of the myvac platform.

Combining Transgene’s own cutting-edge proprietary AI-driven technologies for neoantigen selection with scalable manufacturing capabilities, TG4070 is designed to broaden the application of individualized cancer vaccines across multiple solid tumor indications, at an early stage of the disease.

Transgene has initiated a randomized Phase 1 trial evaluating TG4070 in combination with nivolumab in patients with resected non-small cell lung cancer (NSCLC) following neoadjuvant nivolumab plus chemotherapy (EUCT 2025-520946-31-00). Five clinical sites across France are now open and recruiting, marking an important operational milestone for the study. The aim of the trial is to evaluate the potential of TG4070to prevent relapsein combination with an immune checkpoint inhibitorin patients who remain at risk of recurrence despite current treatment approaches.

Advancing programs and strategic activities

Interest in individualized neoantigen therapies for cancer has recently increased, following the ESMO (Free ESMO Whitepaper) meeting where industry reported late-stage clinical data which could confirm the viability of this approach.

Building on the clinical proof-of-principle results to date from TG4050, Transgene is actively preparing for the efficient initiation of a potential Phase 3 trial following the 2-year DFS results of the ongoing Phase 2 clinical trial, expected in Q1 2028. With TG4070 now entering clinical development, Transgene is also investigating the broader application of its myvac platform which has the potential to generate INTVs against a wide range of tumor types.

Alongside this growing momentum, Transgene continues to engage with potential partners and stakeholders.

Beyond myvac, which remains the focus of the Company, Transgene continues to evaluate the development opportunities for its broader portfolio of viral vector-based immunotherapies, including TG-MVATM and oncolytic viruses. The first patient was enrolled in the investigatorsponsored OV-PRIME-R trial, conducted in collaboration with the University of Copenhagen, evaluating BT-001 in combination with an anti-PD-1 therapy in patients with pMMR (proficient mismatch repair) localized rectal cancer (see press release).

Key financial elements

Operating income amounted to €4.3 million for the first nine months of 2026 compared to €6.1 million for the same period in 2025. It mainly consisted of the Research Tax Credit, amounting to €3.9 million, compared with €5.8 million for the same period in 2025.

As of September 30, 2026, Transgene had €84.3 million in cash, cash equivalents and other current financial assets, compared to €111.9 million as of December 31, 2025.

Transgene’s cash burn1 amounted to €29.5 million in the first nine months of 2026 compared with €28.8 million for the same period in 2025.

Under current plans, the company has sufficient cash to ensure financial visibility until early 2028.

(Press release, Transgene, NOV 9, 2026, View Source [SID1234674487])

Laboratoires Pierre Fabre and XtalPi Announce an AI-Driven Collaboration Focused on Drug Discovery

On November 9, 2026 Laboratoires Pierre Fabre and XtalPi (XtalPi Holdings Limited, 2228.HK) reported an agreement under which they will collaborate on the discovery of novel clinical candidates across a number of research programs in the field of oncology, potentially dermatology, and rare diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, XtalPi will use its integrated AI capabilities and robotics platform to de novo design and deliver novel small molecule therapeutics against undisclosed targets. Laboratoires Pierre Fabre will contribute with its expertise in disease biology, discovery, translational research, and clinical development to select and advance the most promising compounds, and will be responsible for subsequent clinical and commercial development.

The collaboration reflects the parties’ shared interest in exploring challenging and historically hard-to-drug targets—an area associated with significant unmet medical need and substantial opportunity in innovative drug discovery.

For Laboratoires Pierre Fabre, this agreement represents a strategic addition to its R&D roadmap, strengthening its drug discovery capabilities. It also advances XtalPi’s efforts to apply AI and robotics to de novo drug discovery. Together, the companies aim to accelerate the identification of high-quality clinical candidates across multiple research programs in oncology and potentially other therapeutic areas.

Raymond Zheng, Head of Integrated Drug Discovery at XtalPi said: "We are honored to enter into this collaboration with Laboratoires Pierre Fabre, a respected international pharmaceutical company. This partnership combines XtalPi’s AI and robotics capabilities with Laboratoires Pierre Fabre’s established therapeutic development expertise. We aim to advance promising preclinical candidates to benefit patients with unmet medical needs."

Francesco Hofmann, Head of Pharma Research and Development at Laboratoires Pierre Fabre said: "Partnering with XtalPi represents an important milestone for us. Leveraging the expertise of XtalPi on AI to accelerate the delivery of high-quality clinical candidates for multiple targets is a critical addition to our R&D Data and AI roadmap and to our discovery engine".

The agreement includes an upfront payment, multiple milestone payments and downstream economic participation; specific financial terms were not disclosed.

(Press release, Pierre Fabre, NOV 9, 2026, View Source [SID1234674510])

iDEL Therapeutics Enters Global Research Collaboration with Daiichi Sankyo to Develop Multi-Drug Conjugate with Targeted Cytosolic Delivery into Solid Tumor Cells

On November 9, 2026 iDEL Therapeutics reported that it has entered into a research collaboration with Daiichi Sankyo (TSE: 4568) to utilize iDEL’s synthetic shuttle platform for the evaluation of a multi-drug conjugate (MDC) for select solid tumor indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, the multi-year collaboration will focus on the preclinical evaluation of a new class of MDC. The research, led by iDEL and scientists at the Daiichi Sankyo Research Institute Munich, will assess the potential of the MDC relative to an antibody-drug conjugate (ADC) with a comparable payload. Further details of the agreement were not disclosed.

"As one of the world leaders in the development of targeted cancer medicines and ADCs, Daiichi Sankyo is the ideal collaborator to support the research and future development of this novel MDC, enabled by iDEL’s synthetic shuttle technology. The collaboration is a validation of the broad potential of our modular platform," said Marcus Kostka, PhD, Co-Founder and CEO of iDEL Therapeutics. "Our technology is being developed to explore approaches that may help mitigate challenges associated with drug uptake and endosomal entrapment."

Beyond this collaboration, iDEL remains focused on optimizing its differentiated delivery technology to unlock previously undruggable intracellular targets, broaden therapeutic windows and increase treatment flexibility and options for patients with cancer. The company has validated its delivery approach in multiple preclinical in vivo proof-of-concept studies using small molecules, peptide and VHH payloads for intracellular targets and has translated this progress into its preclinical pipeline of MDC and single-domain antibody programs for solid tumors.

(Press release, iDEL Therapeutics, NOV 9, 2026, https://www.globenewswire.com/news-release/2026/11/09/3398086/0/en/idel-therapeutics-enters-global-research-collaboration-with-daiichi-sankyo-to-develop-multi-drug-conjugate-with-targeted-cytosolic-delivery-into-solid-tumor-cells.html [SID1234674527])